Scientists have used a gene therapy technique to reverse symptoms of Rett syndrome in mice, showing the potential for clinical application. Rett syndrome, an X-linked autism disorder that primarily occurs in girls, affects one in about 10,000 children a year.
Researchers at McGill University in Montreal, Canada, have found that sodium acts as a switch for a major neurotransmitter receptor in the brain, known as the kainate receptor.
Multiple myeloma, one of the most common types of blood cancer, has been linked to a gene that's responsible for regulating the aging process in the human body.
These alliances benefit not only pharma companies, which gain access to world-class scientists and robust drug discovery programs, but also academic institutions, which increasingly are realizing that relationships with Big Pharma are more and more vital.
Chronic inflammation has long been thought to have ties to Type 2 diabetes, and now researchers at the National Institutes of Health believe they have discovered what that connection may be. The findings also point to a possible molecular target for treating the disease, which is a growing epidemic in the U.S.
A common ingredient used to fight wrinkles may also have the ability to fight Parkinson's disease. In laboratory tests, researchers found that the chemical, called kinetin, thwarted the death of nerve cells damaged by mutations that cause a hereditary form of Parkinson's.
A malaria shot designed by vaccine maker Inovio Pharmaceuticals killed the disease in infected cells in animals while boosting immune responses, according to a new study.
In rats with tendon injuries that were treated with Pluristem Therapeutics' PLacental eXpanded (PLX) stem cell therapy, animals showed tendon healing at two and four weeks following injection, compared to saline-treated rats, according to the Haifa, Israel-based company.
Seattle BioMed has been awarded a $16.6 million grant from the National Institute of Allergy and Infectious Diseases that will allow it to perform what it believes will be the most comprehensive analysis to date of tuberculosis progression from latent infection to active disease.
The U.K. technology transfer organization MRC Technology and the nonprofit Parkinson's UK are partnering in the search for new therapeutic targets to slow, stop or reverse the progression of Parkinson's diseases.
Scientists may have unlocked a way to therapeutically correct genetic defects by using a new technique that targets and repairs defective genes.
A new stem cell treatment that combines neural stem cells with chemo-radiotherapy drugs could provide a better way to combat glioblastoma, the most common and lethal form of adult brain cancer.
U.K. researchers have discovered what role a newly identified team of proteins play in the process of cell division, and they say that harnessing these proteins could provide a new way to kill cancerous cells.
Biomedical researchers will now be able to apply for access to the whole genome data of an important cell line known as HeLa.
The University of Maryland, Baltimore, has forged new agreements with 5 life sciences companies in the Baltimore-Washington metropolitan region through its commercialization arm, University of Maryland Ventures.
Investigators from the Florida campus of the Scripps Research Institute have found that a compound that favors a certain biological pathway could provide scientists with a roadmap for future development of more effective drugs for addiction.
Scientists may soon be able to find novel ways to treat hepatitis C using a new laboratory model developed by researchers at the Icahn School of Medicine at Mount Sinai in New York.
A drug used since the 1960s to treat Type 2 diabetes appears to prolong both life and good health in middle-aged male mice. If further research supports the early results, the discovery could allow doctors to use the drug to stave off metabolic decline in humans as they grow older.
A compound derived from soybeans and other plants may have HIV-fighting properties, according to new research by scientists at George Mason University.
A team at the La Jolla, CA-based Sanford-Burnham Medical Research Institute has developed a compound called SMIP004 that causes a decrease in the number of androgen receptors--proteins located in prostate cancer cells that are activated by testosterone.